このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cosmos Health マネジメント

マネジメント基準チェック /24

Cosmos Health'sの CEO はGreg Siokasで、 Feb2016年に任命され、の在任期間は 8.33年です。は、会社の株式の8.28%を直接所有しており、その価値は$ 974.82K 。経営陣と取締役会の平均在任期間はそれぞれ6年と5.4年です。

主要情報

Greg Siokas

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	8.4yrs
CEOの所有権	8.3%
経営陣の平均在職期間	6yrs
取締役会の平均在任期間	5.5yrs

経営陣の近況

Recent updates

Slammed 27% Cosmos Health Inc. (NASDAQ:COSM) Screens Well Here But There Might Be A Catch

Feb 23

Cosmos climbs 11% on Cana Laboratories acquisition, expanding product line and integrating vertically

Jul 20

Cosmos Holdings to acquire bone health product portfolio from LIFE NLB

Jul 06

CEO（最高経営責任者

Greg Siokas (59 yo)

8.4yrs

在職期間

US$600,000

報酬

Mr. Grigorios Siokas, also known as Greg, has been the Chairman and Chief Executive Officer of Cosmos Health Inc. (formerly known as Cosmos Holdings Inc.) since February 26, 2016 and served as its Presiden...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Grigorios Siokas	Chairman & CEO	8.4yrs	US$600.00k	8.28% $ 1.5m
Georgios Terzis	Chief Financial Officer	3.7yrs	US$108.12k	0.91% $ 158.6k
Demetrios Demetriades	Secretary & Independent Director	10.5yrs	US$10.00k	0.030% $ 5.2k
Nikolaos Bardakis	Chief Operating Officer	1.4yrs	データなし	0.059% $ 10.4k

6.0yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: COSMの経営陣は経験豊富で経験豊富です（平均在職期間は6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Grigorios Siokas	Chairman & CEO	8.4yrs	US$600.00k	8.28% $ 1.5m
Demetrios Demetriades	Secretary & Independent Director	10.5yrs	US$10.00k	0.030% $ 5.2k
Manfred Ziegler	Independent Director & Member of Advisory Board	1.6yrs	US$10.00k	0.030% $ 5.2k
Anastasios Tzikas	Member of Advisory Board	5.7yrs	データなし	データなし
Anastasios Aslidis	Independent Director	2.3yrs	US$62.50k	0.12% $ 20.8k
Athanasios Kolefas	Member of Advisory Board	5.5yrs	データなし	1.27% $ 223.3k
Alexios Papaconstantinou	Member of Advisory Board	3yrs	データなし	データなし
John Hoidas	Independent Director	7.7yrs	US$10.00k	0.030% $ 5.2k
Orestes Varvitsiotes	Member of Advisory Board	7.5yrs	データなし	データなし
Panagiotis Zoumpoulakis	Member of Advisory Board	2yrs	データなし	データなし
Suhel Bhutawala	Director	less than a year	データなし	0.030% $ 5.2k

5.5yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: COSMの取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

Cosmos Health マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

High number of new and inexperienced directors

High number of new and inexperienced directors

Cosmos Health Inc. Announces Executive and Board Changes

Cosmos Health Inc., Annual General Meeting, Sep 18, 2023

Cosmos Health Inc. Appoints Nikos Bardakis as Chief Operating Officer

Chairman & CEO exercised options to buy US$605k worth of stock.

Recent updates

Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of its Forms 10-K and 10-Q

Cosmos Health Inc. announced delayed 10-Q filing

Cosmos Health Inc. announced delayed annual 10-K filing

Cosmos Health Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

Cosmos Health Inc. Commences Development of Cloudscreen 2.0 the New Iteration of Its Next Generation AI Drug Repurposing Platform

Cosmos Health Inc. Receives Regulatory Approval to Sell Sky Premium Life Products in UAE Nutritional Supplements Market

New major risk - Financial position

Cosmos Health Inc. has filed a Follow-on Equity Offering in the amount of $5.049535 million.

Slammed 27% Cosmos Health Inc. (NASDAQ:COSM) Screens Well Here But There Might Be A Catch

High number of new and inexperienced directors

Cosmos Health Inc. (NasdaqCM:COSM) completed the acquisition of Cloudscreen.

Cosmos Health Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Cosmos Health Inc. (NasdaqCM:COSM) signed an agreement to acquire Cloudscreen.

Cosmos Health Inc. Announces Executive and Board Changes

Cosmos Health Inc. Provides Earnings Guidance for the Year 2023

Cosmos Health Inc., Annual General Meeting, Sep 18, 2023

Cosmos Health Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: US$0.091 loss per share (vs US$23.37 loss in 2Q 2022)

Cosmos Health Inc. announced that it has received $5.25 million in funding

Cosmos Holdings Inc. (NasdaqCM:COSM) acquired 100% stakes in Cana Laboratories S.A. for approximately $1.67 million.

Cosmos Health Inc. Launches Terra Creta

Cosmos Health Inc. entered into letter of intent agreement to acquire Docpharm Arzneimittelvertrieb Gmbh & Co. Kg Auf Aktien.

Cosmos Health Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$33.16 loss per share (vs US$23.74 loss in FY 2021)

Cosmos Health Inc. Appoints Nikos Bardakis as Chief Operating Officer

Cosmos Health Inc. (NasdaqCM:COSM) announces an Equity Buyback for $3 million worth of its shares.

Cosmos Health Inc. announced that it has received $32.52568 million in funding

Cosmos Health Inc. announced that it has received $32.52568 million in funding

Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million.

Cosmos Health Inc. has completed a Follow-on Equity Offering in the amount of $32.52568 million.

Chairman & CEO exercised options to buy US$605k worth of stock.

Cosmos Health Enters the Development Phase for CCX0722, an Innovative Product for Obesity and Weight Management

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.11 loss in 3Q 2021)

Cosmos Holdings Inc., Annual General Meeting, Dec 02, 2022

Cosmos Holdings Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a non-binding letter of intent agreement to acquire ZipDoctor, Inc from American International Holdings Corp. (OTCPK:AMIH).

Cosmos Holdings intends to acquire telemedicine platform ZipDoctor

Cosmos Holdings reports Q2 results

Cosmos Holdings Inc. announced delayed 10-Q filing

Cosmos Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price

Cosmos changes name to Cosmos Healthto

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into a binding letter of intent to acquire Cana Laboratories S.A.

Cosmos climbs 11% on Cana Laboratories acquisition, expanding product line and integrating vertically

Cosmos Holdings, Inc. Appoints Dr. Panagiotis Zoumpoulakis to its Advisory Board

Cosmos Holdings Inc. (NasdaqCM:COSM) entered into an agreement to acquire product portfolio of Life NLB, Ltd.

Cosmos Holdings to acquire bone health product portfolio from LIFE NLB

Cosmos Holdings Inc. announced delayed 10-Q filing

Cosmos Holdings Inc. announced delayed annual 10-K filing

Cosmos Holdings Inc. announced delayed annual 10-K filing

Cosmos Holdings, Inc. Launches Osteodome in EU

Cosmos Holdings Inc. Launches New Proprietary Enhanced Dietary Supplement

Cosmos Holdings Inc. Appoints Georgios Terzis as Chief Financial Officer

Cosmos Holdings Inc. Announces David Lowenstein Agrees to Join Cosmos Board of Directors

Cosmos Holdings Inc. Announces Executive Changes

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24